

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HANGZHOU TIGERMED CONSULTING CO., LTD.

杭州泰格醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3347)

CHANGE OF PAYMENT DATE OF FINAL DIVIDEND OF H SHARES

Reference is made to the annual results announcement of Hangzhou Tigermed Consulting Co., Ltd. (the “**Company**”) for the year ended December 31, 2025 dated March 30, 2026, the 2025 annual report of the Company published on April 29, 2026, the circular of the Company dated April 30, 2026 and the announcement of the Company dated June 2, 2026 (together, the “**Announcements**”) in relation to, inter alia, payment of the final dividend for the year ended December 31, 2025 in respect of the H Shares.

The Company hereby announces that the payment date of the final dividend for the year 2025 declared in respect of the H Shares will be changed to July 22, 2026.

Save as disclosed above, all other information and content contained in the Announcements remains unchanged.

An announcement regarding the details of the distribution of the final dividend of A Shares will be published on the website of the Shenzhen Stock Exchange (<http://www.szse.cn>) for information of the Company's shareholders of A Shares.

By order of the Board
Hangzhou Tigermed Consulting Co., Ltd.
Ye Xiaoping
Chairman

Hong Kong, June 30, 2026

As at the date of this announcement, the executive Directors are Dr. Ye Xiaoping, Ms. Cao Xiaochun and Mr. Wen Zengyu; the employee Director is Mr. Wu Hao; and the independent non-executive Directors are Mr. Yuan Huagang, Ms. Liu Yuwen and Mr. Siu, Paul Yu Hay.